These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 20298154)

  • 1. EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?
    Kanwar SS; Nautiyal J; Majumdar AP
    Curr Drug Targets; 2010 Jun; 11(6):682-98. PubMed ID: 20298154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.
    Nautiyal J; Kanwar SS; Majumdar AP
    Curr Protein Pept Sci; 2010 Sep; 11(6):436-50. PubMed ID: 20491625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The epidermal growth factor receptor as a target for gastrointestinal cancer therapy.
    Tedesco KL; Lockhart AC; Berlin JD
    Curr Treat Options Oncol; 2004 Oct; 5(5):393-403. PubMed ID: 15341677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers.
    Desai MD; Saroya BS; Lockhart AC
    Expert Opin Investig Drugs; 2013 Mar; 22(3):341-56. PubMed ID: 23316969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.
    Chen C; Di Bartolomeo M; Corallo S; Strickler JH; Goyal L
    Am Soc Clin Oncol Educ Book; 2020 May; 40():161-173. PubMed ID: 32421451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor blockade: an emerging therapeutic modality in gastroenterology.
    Barnard J
    Gastroenterology; 2001 Jun; 120(7):1872-4. PubMed ID: 11375969
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.
    Gholamin S; Fiuji H; Maftouh M; Mirhafez R; Shandiz FH; Avan A
    Curr Drug Targets; 2014; 15(14):1302-11. PubMed ID: 25382190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapies in gastrointestinal cancers.
    Nautiyal J; Rishi AK; Majumdar AP
    World J Gastroenterol; 2006 Dec; 12(46):7440-50. PubMed ID: 17167831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aurora kinase A in gastrointestinal cancers: time to target.
    Katsha A; Belkhiri A; Goff L; El-Rifai W
    Mol Cancer; 2015 May; 14():106. PubMed ID: 25987188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas.
    Neuzillet C; Rousseau B; Kocher H; Bourget P; Tournigand C
    Pharmacol Ther; 2017 Jun; 174():145-172. PubMed ID: 28223233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-epidermal growth factor receptor-targeted therapy in upper gastrointestinal tract cancers: a meta-analysis.
    Li A; Huang X; Song Y; Chen X; Sun J; Xu H; Wang Z
    Growth Factors; 2015 Apr; 33(2):113-27. PubMed ID: 25697183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies: focus on a new strategy for gastrointestinal tumors.
    Nicolella D; Maione P; Gridelli C
    Crit Rev Oncol Hematol; 2003 Sep; 47(3):261-71. PubMed ID: 12962900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Third Shot at EGFR: New Opportunities in Cancer Therapy.
    Guardiola S; Varese M; Sánchez-Navarro M; Giralt E
    Trends Pharmacol Sci; 2019 Dec; 40(12):941-955. PubMed ID: 31706618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.
    An Z; Aksoy O; Zheng T; Fan QW; Weiss WA
    Oncogene; 2018 Mar; 37(12):1561-1575. PubMed ID: 29321659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Met, IGF1R, and other new targets in upper GI malignancies.
    Popa EC; Shah MA
    Curr Treat Options Oncol; 2013 Sep; 14(3):321-36. PubMed ID: 23873272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological background of EGFR targeting.
    Castillo L; Etienne-Grimaldi MC; Fischel JL; Formento P; Magné N; Milano G
    Ann Oncol; 2004 Jul; 15(7):1007-12. PubMed ID: 15205192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of targeted therapy for gastrointestinal tumors.
    Rolfo C; Bronte G; Sortino G; Papadimitriou K; Passiglia F; Fiorentino E; Marogy G; Russo A; Peeters M
    Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):875-85. PubMed ID: 24957206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting novel molecular targets in gastrointestinal cancers.
    Ma WW; Hidalgo M
    World J Gastroenterol; 2007 Nov; 13(44):5845-56. PubMed ID: 17990350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.